(RTTNews) - Arrowhead Pharmaceuticals, Inc. (ARWR) Monday announced positive topline results from Part 2 of a Phase 1/2 study of ARO-C3 in patients with IgA nephropathy (IgAN).
ARO-C3 is designed to reduce hepatocyte production of complement component 3 (C3) as a potential treatment for various complement mediated renal diseases.
In Part 2 of the Phase 1/2 study, adult patients with C3 Glomerulopathy (C3G) and IgA Nephropathy (IgAN) received 3 doses of ARO-C3. Maximum mean reduction in C3 of 89 percent and mean sustained reduction of greater than 87 percent through week 24 in patients treated with ARO-C3 were observed. Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41 was achieved by week 24.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
